Azelnidipine inhibits aldosterone synthesis and secretion in human adrenocortical cell line NCI-H295R

European Journal of Pharmacology

Volumn 605, Issue 1-3, 2009, Pages 49-52

  Isaka, Tsuyoshi ^a   Ikeda, Keiichi ^a   Takada, Yuko ^a   Inada, Yuri ^a   Tojo, Katsuyoshi ^a   Tajima, Naoko ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Aldosterone; Azelnidipine; Efonidipine; H295R adrenocortical cell; Nifedipine

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE; ANGIOTENSIN II; AZELNIDIPINE; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL T TYPE; EFONIDIPINE; POTASSIUM CHLORIDE; STEROID 11BETA MONOOXYGENASE;

ADRENAL CORTEX CELL; ALDOSTERONE RELEASE; ARTICLE; CONTROLLED STUDY; HORMONE INHIBITION; HORMONE SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ALDOSTERONE; ALDOSTERONE SYNTHASE; ANGIOTENSIN II; AZETIDINECARBOXYLIC ACID; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CALCIUM CHANNELS, T-TYPE; CELL LINE, TUMOR; DIHYDROPYRIDINES; GENE EXPRESSION REGULATION; HUMANS; NITROPHENOLS; ORGANOPHOSPHORUS COMPOUNDS; POTASSIUM CHLORIDE; STEROID 11-BETA-HYDROXYLASE;

EID: 60449109932     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.12.041     Document Type: Article

References (24)

1. 2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R. Eur. J. Pharmacol. 584 (2008) 424-434
2. 2+ at the level of steroidogenic cytochromes P450 and 3βHSD expression in H295R cells. Endocr. Res. 24 (1998) 345-354
3. Clyne C.D., White P.C., and Rainey W.E. Calcium regulates human CYP11B2 transcription. Endocr. Res. 22 (1996) 485-492
4. Denner K., Rainey W.E., Pezzi V., Bird I.M., Bernhardt R., and Mathis J.M. Differential regulation of 11β-hydroxylase and aldosterone synthase in human adrenocortical H295R cells. Mol. Cell. Endocrinol. 121 (1996) 87-91
5. 2+ channel inhibition by G protein β2γ2 subunits. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 14590-14595
6. Fiebeler A., Muller D.N., Shagdarsuren E., and Luft F.C. Aldosterone, mineralocorticoid receptors, and vascular inflammation. Curr. Opin. Nephrol. Hypertens. 16 (2007) 134-142
7. George J., and Struthers A.D. Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure. Expert. Opin. Pharmacother. 8 (2007) 3053-3059
8. Imagawa K., Okayama S., Takaoka M., Kawata H., Naya N., Nakajima T., Horii M., Uemura S., and Saito Y. Inhibitory effect of efonidipine on aldosterone synthesis and secretion in human adrenocarcinoma (H295R) cells. J. Cardiovasc. Pharmacol. 47 (2006) 133-138
9. Koike H., Kimura T., Kawasaki T., Sada T., Ikeda T., Sanbuissho A., and Saito H. Azelnidipine, a long-acting calcium channel blocker with slow onset and high vascular affinity. Annu. Rep. Sankyo. Res. Lab. 54 (2002) 1-64
10. Lesouhaitier O., Chiappe A., and Rossier M.F. Aldosterone increases T-type calcium currents in human adrenocarcinoma (H295R) cells by inducing channel expression. Endocrinology 142 (2001) 4320-4330
11. Li J.M., Iwai M., Cui T.X., Min L.J., Tsuda M., Iwanami J., Suzuki J., Mogi M., and Horiuchi M. Effect of azelnidipine on angiotensin II-mediated growth-promoting signaling in vascular smooth muscle cells. Mol. Pharmacol. 67 (2005) 1666-1673
12. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25 (2001) 402-408
13. Marney A.M., and Brown N.J. Aldosterone and end-organ damage. Clin. Sci. (Lond). 113 (2007) 267-278
14. Matsui T., Yamagishi S., Nakamura K., Kikuchi S., and Inoue H. Azelnidipine, a dihydropyridine-based calcium antagonist, inhibits angiotensin II-induced oxidative stress generation and downregulation of pigment epithelium-derived factor mRNA levels in microvascular endothelial cells. Drugs Exp. Clin. Res. 31 (2005) 215-219
15. Nakamura T., Saito Y., Saito T., and Kurabayashi M. Azelnidipine down-regulates renal angiotensin-converting enzyme and mineralocorticoid receptor mRNA in diabetic hypertensive rats. J. Pharmacol. Sci. 102 (2006) 239-242
16. Oizumi K., Nishino H., Miyamoto M., Fukushige J., Fukami M., and Koike H. Beneficial renal effects of CS-905, a novel dihydropyridine calcium blocker, in SHR. Jpn. J. Pharmacol. 51 (1989) 501-508
17. 2+ channels with efonidipine decreased plasma aldosterone concentration in healthy volunteers. Hypertens. Res. 29 (2006) 493-497
18. Rader D.J., and Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. Nature 451 (2008) 904-913
19. Rossier M.F., Ertel E.A., Vallotton M.B., and Capponi A.M. Inhibitory action of mibefradil on calcium signaling and aldosterone synthesis in bovine adrenal glomerulosa cells. J. Pharmacol. Exp. Ther. 287 (1998) 824-831
20. Saito T., Itoh H., Chun T.H., Fukunaga Y., Yamashita J., Doi K., Tanaka T., Inoue M., Masatsugu K., Sawada N., Sakaguchi S., Arai H., Mukoyama M., Tojo K., Hosoya T., and Nakao K. Coordinate regulation of endothelin and adrenomedullin secretion by oxidative stress in endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 281 (2001) H1364-1371
21. Schirpenbach C., and Reincke M. Primary aldosteronism: current knowledge and controversies in Conn's syndrome. Nat. Clin. Pract. Endocrinol. Metab. 3 (2007) 220-227
22. Unger T., Jakobsen A., Heroys J., Ralph A., Rees T., and Shaw M. Targeting cardiovascular protection: the concept of dual renin-angiotensin system control. Medscape. J. Med. 10 Suppl, S4 (2008)
23. Wellington, K., Scott, L.J., 2003. Azelnidipine. Drugs 63, 2613-2621; discussion 2623-2614.
24. Yagil Y., Miyamoto M., Frasier L., Oizumi K., and Koike H. Effects of CS-905, a novel dihydropyridine calcium channel blocker, on arterial pressure, renal excretory function, and inner medullary blood flow in the rat. Am. J. Hypertens. 7 (1994) 637-646